Rise and shine, everyone, another hot day is on the way. The forecast – at least on this side of the pond – is warning us to find some shade. So to prepare, we are grabbing a parasol and, naturally, brewing a few cups of stimulation to see us through. Our choice today is orange creme. No matter the weather, though, there is work to be done. So please enjoy the latest items of interest assembled below. We hope your journey is productive, meaningful and comfortable. And as always, do keep in touch. We have adjusted our settings to accept postcards and telegrams…
After taking legal action last year, Eli Lilly filed even more lawsuits against several spas, compounders and wellness centers over unapproved versions of tirzepatide, which is the active ingredient in Mounjaro and Zepbound, STAT notes. The company argued this group of businesses is the latest to misleadingly use the brand names of its widely used medicines, posing dangers for patient safety. Lilly also issued an open letter warning the public about the risks of these products. With the immense demand for GLP-1-based drugs and recurring shortages of the branded treatments, a wide variety of businesses have popped up to offer their own versions of what they claim are GLP-1 drugs.
South Africa’s public health care system has run out of the human insulin pens that it provides to people with diabetes, as the pharmaceutical industry shifts production priorities to blockbuster weight-loss drugs that use a similar device for delivery, The New York Times writes. Novo Nordisk, which has supplied South Africa with human insulin in pens for a decade, opted not to renew its contract, which expired last month. No other company has bid on the contract — to supply 14 million pens for the next three years, at about $2 per pen. The shortage highlights a widening gulf in the standard of care for people with diabetes, most of whom live in low-income countries.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect